title: A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancer.
abstract: OBJECTIVE
  To compare the effectiveness of adjuvant chemotherapy regimens in triple negative breast cancer (TNBC) for which no protocol has been determined to be treatment of choice.
  
  
  METHODS
  In this single-center retrospective trial, we analyzed the adjuvant regimens of 164 TNBC patients among 3253 breast cancer patient records. Adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), CAF (cyclophosphamide, doxorubicin, 5fluorouracil), and AC-T (doxorubicin, cyclophosphamide followed by docetaxel) regimens were compared in terms of disease free survival (DFS) and overall survival (OS).
  
  
  RESULTS
  In terms of both DFS and OS TAC was significantly superior to AC-T in node positive TNBC. When node negative and positive patients were analyzed together, TAC was still significantly superior to AC-T in terms of DFS and OS. There was a trend favoring CAF over AC-T, however, it was only significant in terms of OS when all node negative and positive TNBC patients were incorporated together.
  
  
  CONCLUSIONS
  In the adjuvant setting, especially in node positive patients, TAC should be the treatment of choice in TNBC patients. CAF is probably better than AC-T in TNBC.
authors.affiliation: Department of Medical Oncology, Gaziantep University School of Medicine, Gaziantep, Ankara, Turkey.
authors.forename: Hakan
authors.initials: H
authors.lastname: Buyukhatipoglu
authors.forename: Taner
authors.initials: T
authors.lastname: Babacan
authors.forename: Neyran
authors.initials: N
authors.lastname: Kertmen
authors.forename: Ozan
authors.initials: O
authors.lastname: Balakan
authors.forename: Ali
authors.initials: A
authors.lastname: Suner
authors.forename: Ozturk
authors.initials: O
authors.lastname: Ates
authors.forename: Furkan
authors.initials: F
authors.lastname: Sarici
authors.forename: Alma
authors.initials: A
authors.lastname: Aslan
authors.forename: Omer
authors.initials: O
authors.lastname: Diker
authors.forename: Vildan
authors.initials: V
authors.lastname: Tasdemir
authors.forename: Yavuz
authors.initials: Y
authors.lastname: Ozisik
authors.forename: Kadri
authors.initials: K
authors.lastname: Altundag
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D018579:Patient Selection; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D043823:Taxoids / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome; D064726:Triple Negative Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D014421:Turkey
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil